VivoSeq
Infectious Disease

Diphtheria

49

Pipeline Programs↗

8

Active Trials↗

14

Companies Involved↗

Diphtheria is a moderately active landscape with 49 programs across 14 companies. The most active players are MassBiologics, Roche, Changchun BCHT Biotechnology Co.. 15 therapies are approved with 20 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

MassBiologics

1 program

Phase 1Roche logo

Roche

1 program

Phase 1C

Changchun BCHT Biotechnology Co.

2 programs

Phase 3Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd

2 programs

Phase 3B

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

1 program

Phase 3Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Vaccine

33 of 37 classified programs — the dominant modality here.

11%ALL OTHERSSmall molecule411%

Vaccine leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 71 pipeline programs.

Analysis

Trial Status

47

clinical trials

Completed36 · 77%
Recruiting3 · 6%
Unknown status3 · 6%
Not yet recruiting2 · 4%
Active, not recruiting2 · 4%
Enrolling by invitation1 · 2%

Clinical Trials

Trial Activity

47 trials

Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
Recruiting·IInstitute of Medical Biology, Chinese Academy of Medical Sciences·Phase 1·NCT06184542·460 enrolled
Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants
Recruiting·BBeijing Zhifei Lvzhu Biopharmaceutical Co., Ltd·Phase 3·NCT06344065·1,584 enrolled
Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
Recruiting·CChangchun BCHT Biotechnology Co.·Phase 3·NCT07112144·1,650 enrolled
A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Active, not recruiting·CChina National Biotec Group Company Limited·Phase 3·NCT05091619·2,898 enrolled
A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
Active, not recruiting·CanSino Biologics Inc. logoCanSino Biologics Inc.·Phase 3·NCT05951725·2,520 enrolled
A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
Not yet recruiting·CChangchun BCHT Biotechnology Co.·Phase 1·NCT07492303·96 enrolled
Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine
Not yet recruiting·IInstitute of Medical Biology, Chinese Academy of Medical Sciences·Phase 1/2·NCT07418372·660 enrolled
BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
Enrolling by invitation·BBandim Health Project·Phase 4·NCT07005726·6,000 enrolled
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
Completed·Pfizer logoPfizer·Phase 3·NCT01200368·551 enrolled
Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam
Completed·Sanofi logoSanofi·Phase 2·NCT02640404·224 enrolled
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00325130·1,042 enrolled
Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects
Completed·MMassBiologics·Phase 1·NCT04075175·41 enrolled
Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age
Completed·Sanofi logoSanofi·Phase 2·NCT00643916·378 enrolled
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease
Completed·GSK logoGSK·Phase 4·NCT00282295·1,344 enrolled
Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine
Completed·Centers for Disease Control and Prevention·Phase 1·NCT00164411·30 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)